Growth Capital • Life Science

Riverside Invests In Avance Clinical

On November 9, 2021, private equity firm Riverside invested in life science company Avance Clinical

Investment Context

This is Riverside’s 8th transaction in the Life Science sector.
This is Riverside’s 12th transaction in Australia.

Explore All 401 Growth Capital Life Science Deals - Search the Database Free

Investment Summary
Date	November 9, 2021
Target	Avance Clinical
Sector	Life Science
Investor(s)	Riverside
Deal Type	Growth Capital

Target Company

Avance Clinical

Firle, Australia

Avance Clinical is a Contract Research Organization (CRO) for international biotechs. CRO has been delivering clinical drug development services for international biotechs for FDA and EMA regulatory approval, for the past 24 years. Avance Clinical was founded in 2019 and is based in Firle, Australia.

Explore More Deals

Browse All 215,158 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Investor Overview 1

Investor

Riverside

New York, New York, United States

Investor Investor

Category	Private Equity Firm
Founded	1988
PE ASSETS	5.0B USD
Size	Mega
Type	Sector Agnostic

DESCRIPTION

The Riverside Company is a global private equity firm that seeks investments in profitable lower middle-market companies valued under $400 million. Riverside looks to invest in growth businesses headquartered in North America, Europe, and Asia (primarily Japan and South Korea), that have been in operation for at least five years. Riverside targets investments in a wide array of industries including distribution, automotive, healthcare, education, manufacturing, software, consumer services, plastics, publishing, food, communications, marine, and business services. Riverside was formed in 1988 and is based in New York City.

Deal Context for Investor	#
Overall	268 of 295
Sector: Life Science	8 of 9
Type: Growth Capital	53 of 65
Country: Australia	12 of 14
Year: 2021	12 of 14

PREVIOUS DEAL

DATE	TARGET	DEAL TYPE	VALUE
2021-11-04	Plasti-Fab Calgary, Alberta, Canada Plasti-Fab manufactures insulating building products and technologies that enable residential and commercial structures to be energy-efficient when used as components of a building envelope. Plasti-Fab was founded in 1968 and is headquartered in Calgary, Alberta.	Buy	$178M

DATE

TARGET

DEAL TYPE

VALUE

2021-11-04

Plasti-Fab

Calgary, Alberta, Canada

Plasti-Fab manufactures insulating building products and technologies that enable residential and commercial structures to be energy-efficient when used as components of a building envelope. Plasti-Fab was founded in 1968 and is headquartered in Calgary, Alberta.

Buy

$178M

FOLLOWING DEAL

DATE	TARGET	DEAL TYPE	VALUE
2021-11-11	BISim Prague, Czech Republic BISim is a global software company at the forefront of simulation and training solutions for defense and civilian organizations. Globally, more than 500,000 military personnel are trained every year using BISim’s Virtual Battlespace (VBS) software products. More than 60 NATO and NATO-friendly countries and over 250 integrators/prime contractors use VBS technology, many making significant funding commitments to extend VBS product capabilities. BISim was formed in 2001 and is based in Prague, Czech Republic.	Sell	-

DATE

TARGET

DEAL TYPE

VALUE

2021-11-11

BISim

Prague, Czech Republic

BISim is a global software company at the forefront of simulation and training solutions for defense and civilian organizations. Globally, more than 500,000 military personnel are trained every year using BISim’s Virtual Battlespace (VBS) software products. More than 60 NATO and NATO-friendly countries and over 250 integrators/prime contractors use VBS technology, many making significant funding commitments to extend VBS product capabilities. BISim was formed in 2001 and is based in Prague, Czech Republic.

Sell

Explore Related M&A Activity

Life Science M&A - Growth Capital M&A Deals - Australia M&A - 2021 M&A